Stockscreener 앱 받기
0.7652
3.55%
-0.0282
시간 외 거래:
.79
0.0248
+3.24%
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Can Citius Pharmaceuticals Inc. stock continue upward trendTrade Exit Summary & Verified Momentum Watchlists - mfd.ru
Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - Nasdaq
Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Market Review: Is Citius Pharmaceuticals Inc a cyclical or defensive stockPortfolio Performance Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st
Does Citius Pharmaceuticals Inc. align with a passive investing strategyTrade Volume Report & Daily Technical Forecast Reports - mfd.ru
Aug PostEarnings: Is IMRN subject to activist investor interest2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - Morningstar
What is the earnings history of Citius Pharmaceuticals IncJuly 2025 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Risk Check: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
VIX Spike: Is Citius Pharmaceuticals Inc a potential multi baggerJuly 2025 WrapUp & Smart Allocation Stock Tips - baoquankhu1.vn
Weekly Earnings: Can Howard Hughes Holdings Inc deliver consistent EPS growthEarnings Overview Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Geopolitics Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesTrade Performance Summary & Short-Term Trading Alerts - baoquankhu1.vn
What technical charts say about Citius Pharmaceuticals Inc. stock2025 Earnings Surprises & Weekly Top Stock Performers List - bollywoodhelpline.com
Setup Watch: Whats next for VGASW stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Published on: 2026-01-13 01:39:15 - ulpravda.ru
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Performance Report & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
What hedge fund moves indicate for Citius Pharmaceuticals Inc. (47N0) stockShare Buyback & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Is Citius Pharmaceuticals Inc. stock a top momentum playPortfolio Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
How Citius Pharmaceuticals Inc. (47N0) stock expands through international marketsMarket Growth Report & Consistent Profit Trade Alerts - Улправда
Can Citius Pharmaceuticals Inc. (47N0) stock resist broad market declinesJuly 2025 Big Picture & High Conviction Investment Ideas - Улправда
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Sentiment & Weekly Stock Breakout Alerts - ulpravda.ru
User | poteaudailynews.comCitius Pharmaceuticals, Inc.Common Stock (Nasdaq:CTXR) Stock Quote - FinancialContent
Portfolio Update: Can Citius Pharmaceuticals Inc 47N0 stock resist broad market declinesJuly 2025 Chart Watch & Safe Capital Allocation Plans - Bộ Nội Vụ
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Citius Oncology announces pricing of $9 million public offering - MSN
Press Release: Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛
Fibonacci Retracement Aligns with Support in Thomas Scott India LimitedAnalyst Upgrades & Small Capital Trading Tips - earlytimes.in
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentMarket Sentiment Report & Free Long-Term Investment Planning - earlytimes.in
Citius Pharmaceuticals Inc (CTXRW) Fundamental Analysis - Meyka
Market Outlook: What dividend safety score for Citius Pharmaceuticals Inc stockAnalyst Downgrade & Risk Managed Investment Strategies - Bộ Nội Vụ
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus - Sahm
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
1.12%
0.87%
자본화:
|
볼륨(24시간):